AlTorress

CYTK, MACD Histogram just turned positive

Long
NASDAQ:CYTK   Cytokinetics, Incorporated
This is a Bullish indicator signaling CYTK's price could rise from here. Traders may explore going long the stock or buying call options. Tickeron A.I. dvisor identified 44 similar cases where CYTK's MACD histogram became positive, and 42 of them led to successful outcomes. Odds of Success: 90%. Current price $22.85 crossed the support line at $22.88 and is trading between $22.88 support and $22.14 resistance lines. Throughout the month of 08/26/20 - 09/28/20, the price experienced a -7% Downtrend, while the week of 09/21/20 - 09/28/20 shows a +5% Uptrend.

Bullish Trend Analysis
The RSI Oscillator points to a transition from a downward trend to an upward trend -- in cases where CYTK's RSI Oscillator exited the oversold zone, Tickeron AI shows that in 19 of 22 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 86%.

The Stochastic Indicator suggests the stock price trend may be in a reversal from a downward trend to an upward trend. 46 of 54 cases where CYTK's Stochastic Oscillator exited the oversold zone resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 81%.

Following a +11.06% 3-day Advance, the price is estimated to grow further. Considering data from situations where CYTK advanced for three days, in 263 of 308 cases, the price rose further within the following month. The odds of a continued upward trend are 85%.

CYTK may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.

The Aroon Indicator entered an Uptrend today. Tickeron AI shows that in 218 of 252 cases where CYTK Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 87%.
Disclaimer

The information and publications are not meant to be, and do not constitute, financial, investment, trading, or other types of advice or recommendations supplied or endorsed by TradingView. Read more in the Terms of Use.